Compare JAGX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | PRFX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | Israel |
| Employees | 47 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.6M |
| IPO Year | 2014 | 2020 |
| Metric | JAGX | PRFX |
|---|---|---|
| Price | $2.73 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 71.5K | ★ 1.8M |
| Earning Date | 04-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | N/A |
| Revenue This Year | $61.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.58 |
| 52 Week High | $8.00 | $5.39 |
| Indicator | JAGX | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 43.87 |
| Support Level | $1.74 | $0.95 |
| Resistance Level | $4.13 | $1.54 |
| Average True Range (ATR) | 0.39 | 0.40 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 2.11 | 5.72 |
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.